- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nutraplus starts production of Lumefantrine at Tarapur plant
New Delhi: Pharma firm Nutraplus India has started commercial production of anti-malarial drug Lumefantrine at its new plant at Tarapur in Maharashtra."Previously company was engaged in the manufacturing of intermediate of the same drug... and was selling to various pharma companies," Nutraplus India said in a filing to BSE.Now, it is manufacturing the final end product at the company's...
New Delhi: Pharma firm Nutraplus India has started commercial production of anti-malarial drug Lumefantrine at its new plant at Tarapur in Maharashtra.
"Previously company was engaged in the manufacturing of intermediate of the same drug... and was selling to various pharma companies," Nutraplus India said in a filing to BSE.
Now, it is manufacturing the final end product at the company's new production facilities, it added.
Saying that this adds to the margins for the company, Nutraplus India said: "This is a forward integration and shall result in better margin."
The company expects to achieve full production capacities in next three months in the plant, it added.
"Previously company was engaged in the manufacturing of intermediate of the same drug... and was selling to various pharma companies," Nutraplus India said in a filing to BSE.
Now, it is manufacturing the final end product at the company's new production facilities, it added.
Saying that this adds to the margins for the company, Nutraplus India said: "This is a forward integration and shall result in better margin."
The company expects to achieve full production capacities in next three months in the plant, it added.
Next Story